Moolec Science (MLECW) Cash from Financing Activities (2022 - 2024)
Moolec Science (MLECW) posted Cash from Financing Activities of -$8.9 million for Q4 2024, down 1533.11% sequentially from -$542417.0 in Q3 2024, and up 62.11% YoY from -$5.5 million in Q1 2024.
Moolec Science (MLECW) Cash from Financing Activities (2022 - 2024) Analysis & Trends
Moolec Science has reported Cash from Financing Activities for 3 years, with the latest figure at -$8.9 million in Q4 2024.
- Quarterly Cash from Financing Activities rose 62.11% year-over-year to -$8.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$15.6 million (down 136.49% YoY) and the FY2025 annual result came in at -$15.0 million, down 906.47% from the prior year.
- Cash from Financing Activities slipped to -$8.9 million in Q4 2024 per MLECW's latest filing, from -$542417.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $66.2 million in Q2 2023 and troughed at -$23.4 million in Q4 2023.
- A 3-year average of $3.5 million and a median of -$334930.5 in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 13144.74% in 2023, then sank 325.61% in 2024.
- Over 3 years, Cash from Financing Activities stood at $500000.0 in 2022, then slumped by 4775.75% to -$23.4 million in 2023, then soared by 62.11% to -$8.9 million in 2024.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$8.9 million, -$542417.0, and -$11.0 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -8.86 Mn |
| Dec 31, 2024 | -8.86 Mn |
| Sep 30, 2024 | -542,417.00 |
| Sep 30, 2024 | -542,417.00 |
| Jun 30, 2024 | -11.00 Mn |
| Jun 30, 2024 | -11.00 Mn |
| Mar 31, 2024 | 4.82 Mn |
| Mar 31, 2024 | 4.82 Mn |
| Dec 31, 2023 | -23.38 Mn |
| Dec 31, 2023 | -23.38 Mn |
| Sep 30, 2023 | -127,444.00 |
| Sep 30, 2023 | -127,444.00 |
| Jun 30, 2023 | 66.22 Mn |
| Jun 30, 2023 | 66.22 Mn |
| Jun 30, 2022 | 500,000.00 |
| Jun 30, 2022 | 500,000.00 |